Pluristem Therapeutics, Inc. (NASDAQ:PSTI) – Biotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food Platform


Pluristem Therapeutics Inc (NASDAQ: PSTI) and Tnuva Group have collaborated to develop, manufacture and commercialize cultured cell-based products for the food industry. 

  • Tnuva Group is the largest food producer in Israel and the Israeli player in the field of alternative dairy and protein products. 
  • The collaboration started with the incorporation of a new company (NewCo) that will receive exclusive, global, royalty-bearing licensing rights to use Pluristem’s proprietary technology in the field of cultured meat.
  • Tnuva Group will invest $7.5 million in NewCo, according to a pre-money valuation of $40 million, with the option to invest up to an additional $7.5 million over a period of 12 months.
  • Pluristem will support the establishment, research, and development activities of NewCo.
  • Tnuva will provide the R&D platform to develop consumer products and receive preferred marketing rights of any developed NewCo products in Israel.
  • NewCo intends to present its technology Proof of Concept in 2022 to launch its first raw cultured meat product in 2023.
  • As part of the collaboration, the Parties may expand the partnership to include cultured dairy and cultured fish products by establishing separate, new ventures.
  • Price Action: PSTI shares are up 21.80% at $1.79 during the premarket session on the last check Monday.



Source link

Leave a Reply

Your email address will not be published.

Copyright © 2022 Billionaire Club Co LLC. All rights reserved

Chat
Loading the chat ...